Additionally, CRISPR/Cas9 was used to knock out the BCL–6 gene in Diffuse Large B-cell Lymphoma (DLBCL), which resulted in stagnation of cell cycle (G1) in tumor cells, bringing hope for curing this disease [90]. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.